# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Steven Lichtman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform and raises the price targ...
Redburn Atlantic analyst Issie Kirby initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Buy rating and announce...
Lake Street analyst Brooks O'Neil maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and raises the price target fr...
Citigroup analyst Joanne Wuensch upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Neutral to Buy and raises the price target...
Stifel analyst Mathew Blackman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and raises the price target from $45 ...